|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02192 MEDLIVE
Nominal 
11.500 +0.300 (+2.679%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 558,455 | 35.546% | 412,004 | 314,054 | 284,440 | 213,529 |
| Cost of Sales | (231,233) | 43.919% | (160,669) | (101,313) | (83,706) | (57,293) |
| Gross Profit | 327,222 | 30.194% | 251,335 | 212,741 | 200,734 | 156,236 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 5 | 12 | (2) | 0 | |
| Profit / (Loss) before Taxation | 340,474 | 34.505% | 253,132 | 135,037 | 69,927 | 104,848 | |
| Taxation | (10,173) | 641.472% | (1,372) | (8,616) | (24,682) | (19,651) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (15,155) | 60.218% | (9,459) | (9,100) | (4,629) | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 315,146 | 30.064% | 242,301 | 117,321 | 40,616 | 85,197 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (203,933) | 11.121% | (183,523) | (65,711) | (7,174) | (240) |
| Depreciation & Amortisation | 15,600 | 66.471% | 9,371 | 8,987 | 6,149 | 5,316 |
| Directors' Emoluments | -- | -- | 10,048 | 13,372 | 11,934 | 2,717 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 43.230 | 28.814% | 33.560 | 16.420 | 6.590 | 15.920 |
| DPS (cts) | 25.710 | -- | 23.150 | 6.540 | 1.700 | -- |
| Dividend Payout Ratio (%) | 59.473% | -- | 68.981% | 39.829% | 25.797% | -- |
| Cash flow per share ($) | -- | -- | 0.141 | 0.108 | 0.072 | 0.208 |
| NBV per share ($) | 6.548 | -- | 6.324 | 6.135 | 5.536 | -- |
| Remarks: | Real time quote last updated: 17/04/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 315,146,000 |
| %Change | 30.064% |
| EPS / (LPS) | RMB 0.432 |
| NBV Per Share (¥) | RMB 6.548 |